PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. More Details
Flawless balance sheet and fair value.
Share Price & News
How has Darya-Varia Laboratoria's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DVLA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: DVLA's weekly volatility (2%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: DVLA underperformed the ID Pharmaceuticals industry which returned 20.4% over the past year.
Return vs Market: DVLA underperformed the ID Market which returned 22.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Darya-Varia Laboratoria's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Darya-Varia Laboratoria undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: DVLA (IDR2350) is trading above our estimate of fair value (IDR1796.97)
Significantly Below Fair Value: DVLA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: DVLA is good value based on its PE Ratio (13.7x) compared to the ID Pharmaceuticals industry average (25x).
PE vs Market: DVLA is good value based on its PE Ratio (13.7x) compared to the ID market (22.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DVLA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DVLA is good value based on its PB Ratio (1.9x) compared to the ID Pharmaceuticals industry average (2.4x).
How is Darya-Varia Laboratoria forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Darya-Varia Laboratoria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Darya-Varia Laboratoria performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVLA has high quality earnings.
Growing Profit Margin: DVLA's current net profit margins (11.4%) are lower than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: DVLA's earnings have grown by 13.5% per year over the past 5 years.
Accelerating Growth: DVLA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DVLA had negative earnings growth (-11%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).
Return on Equity
High ROE: DVLA's Return on Equity (14.1%) is considered low.
How is Darya-Varia Laboratoria's financial position?
Financial Position Analysis
Short Term Liabilities: DVLA's short term assets (IDR1,364.4B) exceed its short term liabilities (IDR419.8B).
Long Term Liabilities: DVLA's short term assets (IDR1,364.4B) exceed its long term liabilities (IDR133.7B).
Debt to Equity History and Analysis
Debt Level: DVLA is debt free.
Reducing Debt: DVLA has not had any debt for past 5 years.
Debt Coverage: DVLA has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: DVLA has no debt, therefore coverage of interest payments is not a concern.
What is Darya-Varia Laboratoria current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: DVLA's dividend (4.55%) is higher than the bottom 25% of dividend payers in the ID market (1.15%).
High Dividend: DVLA's dividend (4.55%) is low compared to the top 25% of dividend payers in the ID market (4.83%).
Stability and Growth of Payments
Stable Dividend: DVLA's dividend payments have been volatile in the past 10 years.
Growing Dividend: DVLA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40.9%), DVLA's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jose Romana (58 yo)
Mr. Jose Sumpaico Romana serves as President Director at PT Darya-Varia Laboratoria Tbk since October 2020. Mr. Romana served as Vice President Director and Director at PT Darya-Varia Laboratoria Tbk since...
Experienced Management: DVLA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: DVLA's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Darya-Varia Laboratoria Tbk's company bio, employee growth, exchange listings and data sources
- Name: PT Darya-Varia Laboratoria Tbk
- Ticker: DVLA
- Exchange: IDX
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: Rp2.632t
- Shares outstanding: 1.12b
- Website: https://www.darya-varia.com
Number of Employees
- PT Darya-Varia Laboratoria Tbk
- Tower C
- South Quarter
- Jakarta Raya
PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia and internationally. It operates in three segments: Prescription Drugs, Consumer ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/10 17:33|
|End of Day Share Price||2021/05/10 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.